Hexavalent vaccines | NITAG RESOURCE CENTER

Overview

In March 2024, WHO prequalified a new hexavalent combination vaccine (DTwP-HepB-Hib-IPV). The evidence summarised here is targeted primarily to countries currently using pentavalent (DTwP-HepB-Hib) and inactivated polio vaccine (IPV) schedules that are considering switching to Hexavalent vaccine (DTwP-HepB-Hib-IPV). This information is also applicable to countries considering switching rom acellular pertussis combination vaccines to the newly prequalified DTwP-HepB-Hib-IPV hexavalent vaccine.

Looking for a comparing key characteristics of different available Hexavalent vaccines?

Compare vaccine type

General indicators for Hexavalent vaccines

Number of new cases per year (last 3-5 years)

Proportion of the population affected by the disease or infected with the antigen

Serogroup or serotype distribution (for serogroup- or serotype-specific vaccines)

Number of deaths from the disease per year

Case Fatality ratio (number of deaths / number of new cases, in %)

Outbreak, epidemic or pandemic risk

Contribution of the vaccine to achievement of the national, regional or global disease goals

Serogroup or serotype coverage by vaccines considered (for serogroup- or serotype-specific vaccines)

Efficacy and effectiveness estimates (e.g. against infection, disease, hospitalization, death), including in different populations

Duration of protection and waning of immunity in general and risk groups

Type, including severity, consequences and frequency of short- and long-term adverse events following vaccination

Perception of the target population on the risk of disease

Acceptability of the vaccine and of vaccination against the disease

Estimated financial cost of materials per vaccine dose (syringes, needles, safety box) (in USD)

Estimated vaccine financial cost per dose (in USD)

Estimated financial cost per person vaccinated (in USD)

Cost-effectiveness ratio

Is there a Gavi programme to support the introduction of this vaccine? If a Gavi programme is available, what support is available to countries?

Available vaccines, licensing status, prequalification status, presentation, formulation, dosage and route of administration

Number of doses and timing of administrations

Cold chain volume required per vaccine dose (in cm3)

Disclaimer

Data are mostly derived from recent WHO and NITAGs official publications, peer reviewed papers and other publicly available sources ; or other institutional publications; data are not the result of a systematic review; data do not cover every aspect of the respective indicator. Users are encouraged to look at data sources in detail and any additional data that may be available (eg. regional and local).